GlaxoSmithKline [NYSE:GSK] announced today that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for the candidate meningococcal and Hib combination vaccine, MenHibrix® (Hib-MenCY-TT). The proposed indication for this combination vaccine is active immunization of infants and toddlers 6 weeks through 15 months of age for the prevention of invasive diseases caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b (Hib).

Issued: Philadelphia, PA

GlaxoSmithKline [NYSE:GSK] announced today that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for the candidate meningococcal and Hib combination vaccine, MenHibrix® (Hib-MenCY-TT). The proposed indication for this combination vaccine is active immunization of infants and toddlers 6 weeks through 15 months of age for the prevention of invasive diseases caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b (Hib). This is the second response letter GSK has received for Hib-MenCY-TT. A Complete Response letter is issued by the FDA when the review of a file is completed and questions remain to be answered prior to approval. GSK will work to respond to the questions posed by the FDA.The company remains committed to making this vaccine available in the United States.

GlaxoSmithKline Biologicals – GlaxoSmithKline Biologicals (GSK Biologicals), GlaxoSmithKline’s vaccines business, is one of the world’s leading vaccine companies and a leader in innovation. The company is active in the fields of vaccine research, development and production with over 30 vaccines approved for marketing and 20 more in development. For further information, please visit www.gsk.com.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information, please visit www.gsk.com.

GlaxoSmithKline enquiries:

UK Media enquiries:

David Mawdsley

(020) 8047 5502

Stephen Rea

(020) 8047 5502

Sarah Spencer

(020) 8047 5502

Janet Morgan

(020) 8047 5502

David Daley

(020) 8047 5502

US Media enquiries:

Nancy Pekarek

(919) 483 2839

Mary Anne Rhyne

(919) 483 2839

Kevin Colgan

(919) 483 2839

Sarah Alspach

(919) 483 2839

Jen Armstrong

(919) 483 2839

European Analyst/Investor enquiries:

Sally Ferguson

(020) 8047 5543

Gary Davies

(020) 8047 5503

Ziba Shamsi

(020) 8047 3289

US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419

Jeff McLaughlin

(215) 751 7002

GlaxoSmithKline cautionary statement regarding forward-looking statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2010.